TD Cowen Initiates Coverage On Opus Genetics with Buy Rating
Opus Genetics Inc IRD
$3.71
▼ -3.39%
($-0.13)
🗓️ Earnings Next Week
Open
$3.86
Prev Close
$3.84
Day Range
$3.62 – $3.86
52W Range
$1.04 – $5.81
Market Cap
$306.32M
Beta
0.58
EPS (TTM)
$-1.32
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2004-11-30 |
| Shares Out. | 82,570,000 |
| Website | opusgtx.com/ ↗ |
| Phone | 12486819815 |
| Employees | 28 |
| Revenue | $2.2M |
| Gross Profit | $2.2M |
| Net Income | -$65.5M |
| Total Assets | $66.8M |
| Total Liabilities | $87.9M |
| Equity | -$45.8M |
About Opus Genetics Inc
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Opus Genetics Inc is a publicly traded company under the ticker symbol IRD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
22 analysts (2026-07-01)